Orchard Therapeutics

NASDAQ: ORTX
Developing treatments for rare diseases using bone-marrow gene therapy.

F-Prime Team

Sector

Life Sciences

Category

Therapeutics

Status

Acquired

Location

London, United Kingdom

Initial Investment

2016
Developing treatments for rare diseases using bone-marrow gene therapy.

Orchard Therapeutics (NASDAQ: ORTX) is a fully integrated commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through innovative gene therapies. Developed LENMELDY to marketing approval in 2024. Acquired by Kyowa Kirin in 2023.

“I couldn’t have created Orchard without F-Prime.”
Bobby Gasper, M.D., Ph.D., CEO